Pharmacovigilance Market revenue to grow from USD 13.61 billion in 2026 to USD 37.04 billion by 2034, representing a 13.33% CAGR during 2026–2034.

Full report: https://www.oganalysis.com/industry-reports/pharmacovigilance-market

Market Overview: Medicine Safety Across the Product Lifecycle

Pharmacovigilance supports the identification, evaluation and prevention of medicine-related harm throughout development and clinical use. Activities include collecting adverse event reports, reviewing individual cases, investigating potential safety signals and communicating risk information. Clinical trials cannot fully establish how medicines perform across every patient group or over prolonged use, so monitoring continues after approval. Pharmaceutical sponsors, healthcare professionals and regulatory authorities rely on these processes to reassess benefits and risks as evidence accumulates.

Commercial opportunities center on reliable case handling, scientific assessment and the systems needed to coordinate safety work across markets. Suppliers are introducing artificial intelligence for information intake and processing, alongside tools that connect reporting channels with existing safety databases. These capabilities may reduce repetitive work and improve access to information. Their value depends on data quality, appropriate validation and qualified medical review. Buyers also need clear accountability, retrievable records and controls that protect confidential safety information.

Key Market Insights: Safety Operations, Technology and Demand

•  Post-approval surveillance remains essential for identifying risks that emerge with wider patient exposure or longer treatment duration.

•  Internal and contracted operating models require shared quality standards, defined responsibilities and consistent access to safety records.

•  AI-assisted intake and processing are prominent supplier priorities, with adoption claims requiring assessment against each organization’s workflows and quality needs.

•  Signal management depends on scientific evaluation and documented decisions; a potential safety signal requires investigation before conclusions are drawn.

•  Real-world information can complement adverse event reports, helping safety teams investigate patterns and evaluate their clinical relevance.

•  Interoperability between intake channels and safety databases is gaining attention as vendors develop more connected and automated workflows.

Market Dynamics: Drivers, Restraints and Market Growth Opportunities

•  Driver: Regulatory reporting, periodic safety reviews and risk management activities create recurring demand for qualified personnel, software and operational support.

•  Driver: Products supplied across multiple markets require coordinated reporting processes that accommodate different submission standards and responsibilities.

•  Opportunity: Language-model tools can help extract safety information from unstructured material, supporting intake, review and research when appropriately evaluated.

•  Opportunity: Connecting safety databases, clinical information and other evidence can support more complete assessment of potential risks.

•  Restraint: Inconsistent case information and fragmented source systems increase reconciliation, validation and quality-review requirements.

•  Restraint: Confidentiality, audit trails and reliable record retrieval remain necessary as information moves between sponsors, service providers and technology platforms.

•  Opportunity: Standardized data exchange and coordinated medical review can help providers support global portfolios while retaining local reporting expertise.

Browse for More Information

https://www.oganalysis.com/industry-reports/pharmacovigilance-market

Market Segmentation: Reporting Methods, Delivery Models and Safety Processes

Reporting types include Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining. Delivery models cover In-House and Contract Outsourcing. End-user categories encompass Hospitals, Pharmaceutical Companies and Other End-Users.

Development-stage coverage runs from Preclinical through Phase I, Phase II, Phase III and Phase IV. Process analysis separates Case Data Management, Signal Detection and Risk Management System, allowing readers to compare operating responsibilities and service requirements.

Regional Insights: Reporting Standards and Service Opportunities

•  North America: U.S. electronic reporting requirements for covered commercial IND safety reports reinforce the importance of standardized data exchange, submission readiness and dependable case assessment.

•  Europe: Established good pharmacovigilance practices support demand for quality systems, signal management, risk planning and documented safety oversight across product lifecycles.

•  Asia-Pacific: Localized reporting and multilingual operations are important service considerations. India’s pharmacy QR-code initiative illustrates efforts to make adverse-reaction reporting more accessible.

•  Middle East & Africa: Opportunities include staff training, local safety support and digital reporting tools that help organizations build consistent, traceable surveillance processes.

•  South & Central America: Local-language case handling, regulatory intelligence and coordination with national reporting channels can support sponsors managing products across several jurisdictions.

Competitive Landscape: Safety Expertise and Connected Technology

Competition spans contract research organizations, specialist safety providers, consulting firms and software vendors. Recent supplier announcements emphasize AI-assisted intake, connected data flows and compatibility with existing safety systems. These priorities suggest that buyers will assess operational reliability and integration capability alongside scientific expertise. Successful implementation also requires defined review responsibilities and evidence that automated processes work within the intended quality system. Flexible technology and service arrangements can help sponsors adapt as portfolio needs change.

Companies covered include IQVIA, Parexel, ICON, ArisGlobal, Cognizant, Accenture, Capgemini, Wipro, Syneos Health, Quanticate, Ergomed Group and United BioSource (UBC).

Recent Developments

•  September 2026: Veeva announced Falcon Safety for AI-supported adverse-event intake and processing across E2B-compatible systems, with availability for early adopters planned for November 2026. Source

•  April 2026: FDA’s E2B(R3) electronic submission requirement took effect for covered commercial IND reports of serious and unexpected suspected adverse reactions through its AEMS database. Source

•  March 2026: Researchers published a preprint describing an EU-focused, time-indexed reference dataset using language-model extraction of product information to evaluate pharmacovigilance signal detection methods. Source

•  January 2026: ArisGlobal reported increased adoption of LifeSphere and NavaX AI capabilities, highlighting developments in safety-data analytics, connected workflows and further deployment plans. Source

•  December 2025: FDA issued final guidance on sponsor safety reporting and assessment for IND and bioavailability/bioequivalence studies, addressing reporting practices and aggregate safety evaluation. Source

•  November 2025: India’s CDSCO directed licensing authorities to ensure pharmacies display PvPI adverse-reaction reporting QR codes and contact details to improve access to reporting. Source

•  October 2025: Graph AI announced USD 3 million in seed funding led by Bessemer Venture Partners to expand product development, engineering and adoption of its pharmacovigilance platform. Source